No 'additive' cardioprotective effect of GLP-1RA on background use of SGLT2i in HARMONY, AMPLITUDE-O and most recently SOUL. Cardioprotective effects of GLP-1RA are 'independent' of SGLT2i ahajournals.org/doi/epdf/10.11… 10.1016/j.jacc.2023.05.048

Warrior trial PEP result shown below. Is this a NULL trial or a NEGATIVE trial? Trial powered for HR 0.80 which was excluded by 95% CI How many null or negative PRAGMATIC trials before we seriously consider/scrutinize the utility of such trials?

Very proud of this work with @kaulcsmc.bsky.social just published in Progress in Cardiovascular Diseases Are ORBITA trials practice-changing? We discuss whether the enthousiasm of some after ORBITA-2 is really justified. www.sciencedirect.com/science/arti... #medsky #cardiosky

Snake oil salesmen of the 21st century! Here they come. endpts.com/rfk-jr-conve...

Are the Device Approval Standards Lax? JACC Cardiovasc Interv. 2025 Feb 10;18(3):380-384. doi: 10.1016/j.jcin.2024.08.037. PMID: 39939040. Device Approval in the United States: The FDA Is on Target. JACC Cardiovasc Interv. 2025 Feb 10;18(3):385-387. doi: 10.1016/j.jcin.2024.10.044. PMID: 39939041.

Editorial on the renal results of FINEARTS HF in @jaccjournals.bsky.social from @kaulcsmc.bsky.social and moi Free link: authors.elsevier.com/a/1kQ%7Ec2d9... #NephSky #CardioSky #Finerenone

Imagine if I excluded centers in a multicenter trial of SAVR vs TAVR where TAVR outperformed SAVR, I could show that SAVR was superior to TAVR in high-risk patients with AS (PARTNER-1A).

Should Heart Failure Trials routinely report on all-cause hospitalizations? Should clinicians, guidelines & payers favor interventions that favorably impact cause-specific & all-cause outcomes? jamanetwork.com/journals/jaman… jamanetwork.com/journals/jaman 

As expected! www.statnews.com/2024/11/22/b...

1/ Is LDL-C lowering by CETP inhibitor cardioprotective? Brief history ACCELERATE (Evacetrapib), N=12092, F/U: 28m Mean LDL 81; LDL⬇️37%, Lp(a)⬇️22% PEP (MACE-5): 12.9% vs 12.8% HR 1.01, 0.91-1.11 Trial stopped early due to futility x.com/mdavidsonmd/...

1/ OPTION LAAC device vs DOAC post a fib ablation N=1600, f/u 3y PEP (death, stroke or SE) NI margin 5% RD, 1.5 RR Result: 41 vs 44, 5.3% vs 5.8% (c/w 10% assumed), RD: -0.5%, UL 1.8%; HR 0.91, 0.59-1.39 NI met for RD and RR margin www.nejm.org/doi/full/10....

1/ SUMMIT Torzepatide in HFpEF in patients with BMI>30 (N=731) F/U 2y PEP: 1. CV death or worsening HF 2. Change in KCCQ-CSS Key results: PEP, HR 0.62, 0.41-0.95, p=0.03 kCCQ improved along with 6MWD, weight loss, SBP, & CRP. Slight ⬆️ in HR GI AEs ⬆️ www.nejm.org/doi/full/10....

1/ BPROAD (N=12821) F/U 4.2y SBP delta: 16.7 (118.3 vs 135 median) A1C at 48m = 7.6% PEP (CV death, MI, stroke or HF): 393 vs 492, 0.79, 0.69-0.90 ARD = 1.55% (6.13% vs 7.68%) PEP driven by stroke: 284 vs 356, HR 0.79, 0.67-0.92 Stroke dominated PEP No diff. in serious AE

1/ Key trials at AHA 2024 BPROAD Intensive BP lowering (SBP<120) vs standard treatment (SBP <140) in diabetes. PEP: 4-MACE (CV death, MI, stroke or HHF) ACCORD failed to validate the hypothesis that SBP target of <120 was the optimal target in diabetes.

Albuminuria is a strong ‘prognostic’ biomarker for kidney and CV risk across a wide spectrum of CKM syndrome. Is it a reliable ‘predictor’ biomarker (lowering it reduces risk) for: 1. Kidney & CV (including HF) risk in CKD? 2. Kidney and HF risk in HF? www.ahajournals.org/doi/10.1161/...